Nabriva Therapeutics Plc

(OTC) NBRVF

Current Price$0.00

Market CapN/A

Since IPO (2015)-100%

5 Year-100%

1 Year-99%

1 Month-100%

Nabriva Therapeutics Plc Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$29.39M

Net Income (TTM)

$55.05M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-242.26 (Low)

Dividend

$0.00

Beta (Volatility)

-242.26 (Low)

Price

$0.00

Volume

Open

$0.00

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Dividend

$0.00

Beta (Volatility)

-242.26 (Low)

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

NBRVF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nabriva Therapeutics Plc

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Theodore R. Schroeder

Website

www.nabriva.com

Headquarters

Dublin, 4, IE

NBRVF Financials

Key Financial Metrics (TTM)

Gross Margin

20%

Operating Margin

-2%

Net Income Margin

-2%

Return on Equity

Return on Capital

-13%

Return on Assets

-2%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$0.00

Shares Outstanding

3.23M

Volume

Avg. Volume

154.758

Financials (TTM)

Gross Profit

$7.09M

Operating Income

$55.49M

EBITDA

$54.70M

Operating Cash Flow

$36.71M

Capital Expenditure

$211.00K

Free Cash Flow

$36.92M

Cash & ST Invst.

$12.41M

Total Debt

$5.22M

Nabriva Therapeutics Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2023YOY CHG

Revenue

$2.57M

-70.7%

Gross Profit

$6.50M

-250.4%

Gross Margin

-2.53%

N/A

Market Cap

$0.00

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$12.06M

-8.9%

EBITDA

$12.01M

-16.3%

Quarterly Fundamentals

Name

Q2 2023YOY CHG

Net Cash

$1.64M

-87.3%

Accounts Receivable

$4.44M

-64.1%

Inventory

$0.00

-100.0%

Long Term Debt

$344.00K

-32.8%

Short Term Debt

$196.00K

-97.0%

Return on Assets

-1.80%

N/A

Return on Invested Capital

-13.34%

N/A

Free Cash Flow

$511.00K

+103.9%

Operating Cash Flow

$511.00K

+103.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ELOXEloxx Pharmaceuticals, Inc.

ELOXEloxx Pharmaceuticals, Inc.$0.13-27.78%

MDVLQMedAvail Holdings, Inc.

MDVLQMedAvail Holdings, Inc.$0.00+0.00%

NEXINexImmune, Inc.

NEXINexImmune, Inc.$0.00+0.00%

CDXICardax, Inc.

CDXICardax, Inc.$0.00+0.00%

OMDDOrmand Industries Inc

OMDDOrmand Industries Inc$0.00+0.00%

BIOCQBiocept, Inc.

BIOCQBiocept, Inc.$0.00+0.00%

HTGMQHTG Molecular Diagnostics, Inc.

HTGMQHTG Molecular Diagnostics, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.43+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$50.22-0.03%

RIVNRivian Automotive

RIVNRivian Automotive$15.02-0.08%

FFord Motor Company

FFord Motor Company$11.88-0.02%

Questions About NBRVF

What is the current price of Nabriva Therapeutics Plc?

Nabriva Therapeutics Plc is trading at N/A per share.

What is the 52-week range for Nabriva Therapeutics Plc?

Over the past 52 weeks, Nabriva Therapeutics Plc has traded between N/A and $0.00.

How much debt does Nabriva Therapeutics Plc have?

As of the most recent reporting period, Nabriva Therapeutics Plc reported total debt of $5.22M.

How much cash does Nabriva Therapeutics Plc have on hand?

Nabriva Therapeutics Plc reported $12.54M in cash and cash equivalents in its most recent financial results.

What is Nabriva Therapeutics Plc’s dividend yield?

Nabriva Therapeutics Plc does not currently have a dividend yield.

Nabriva Therapeutics Plc

Nabriva Therapeutics Plc Financials at a Glance

NBRVF News

Why Nabriva Therapeutics Stock Is Falling Today

3 Companies Tackling the Antibiotic-Resistant Bacteria Crisis

Why Nabriva Therapeutics Shares Are Falling Today

Here's Why Nabriva Therapeutics PLC Is Soaring Today

Why Nabriva Therapeutics PLC Is Skyrocketing

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Nabriva Therapeutics Plc

NBRVF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Nabriva Therapeutics Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NBRVF

What is the current price of Nabriva Therapeutics Plc?

What is the 52-week range for Nabriva Therapeutics Plc?

How much debt does Nabriva Therapeutics Plc have?

How much cash does Nabriva Therapeutics Plc have on hand?

What is Nabriva Therapeutics Plc’s dividend yield?

Premium Investing Services